EUVIMEDEUVIMED entdecken
Crossref

Bioprinting of patient-derived heterogeneous renal cell carcinoma organoids for personalized therapy

Shuangshuang Mao iD, Ruiyang Xie, Jianzhong Shou, Yuan Pang iD, Wei Sun

Biofabrication · 01.10.2025 · 17 (4) · 045008

DOI: 10.1088/1758-5090/adecc5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biofabrication, online erschienen am 12.08.2025. Verfasst von Shuangshuang Mao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mechanical Engineering, Biomanufacturing Center, Tsinghua University, Beijing 100084, People's Republic of China. Hauptthemen laut MEDLINE: Organoids, Carcinoma, Renal Cell, Bioprinting, Precision Medicine. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: 111 Project, NMPA Key Laboratory Research Fund, Tsinghua University Institute for Intelligent Healthcare Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor organoids that can accurately recapitulate the pathophysiological characteristics of original tumor are urgently needed for personalized therapy. However, there are few published studies on patient-derived renal cell carcinoma (RCC) heterogeneous organoids for drug testing to account for patient-specific heterogeneous clinical responses, which has significantly impeded research in the field. Traditional RCC organoid technologies involving matrigel droplets require intensive manual manipulation and are hampered by variability, functional immaturity, low throughput, and limited scale. Here, we applied extrusion-based high-throughput bioprinter to rapidly generate heterogeneous RCC organoids with uniform size, realizing batch automated stable construction and quality control. Bioprinted RCC organoids reserved the pathological morphology and gene mutation/expression characteristics of original tumor and demonstrate interorganoid and interpatient heterogeneity even after long-term cultivation, which are suitable for preclinical patient-specific drug screening testing. Finally, we created multicellular assembloids by reconstituting RCC aggregates with stromal components to generate an organized architecture with in vivo -like vascular morphology and spatial tumor microenvironment heterogeneity. Thus, we have demonstrated the wide-ranging biomedical utility of bioprinted organoids in furthering our understanding of the physiological mechanisms of tumors and the development of personalized treatment methods.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OrganoidsCarcinoma, Renal CellBioprintingPrecision MedicineKidney NeoplasmsHumansTumor Microenvironment

Stichwörter der Autor:innen

RCC organoidsbioprintingdrug evaluationpersonalized therapytumor heterogeneity

Autor:innen und Institutionen

  • Department of Mechanical Engineering, Biomanufacturing Center, Tsinghua University, Beijing 100084, People's Republic of China.
  • Institute for Intelligent Healthcare, Tsinghua University, Haidian District, Beijing 100084, People's Republic of China.
  • Department of Urology, Peking University Third Hospital, Beijing 100191, People's Republic of China.
  • Department of Urology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, People's Republic of China.
  • Department of Mechanical Engineering, Drexel University, Philadelphia, PA 19130, United States of America.

ORCID-Profile: Shuangshuang Mao, Yuan Pang

Förderung

  • 111 Project
  • NMPA Key Laboratory Research Fund
  • Tsinghua University Institute for Intelligent Healthcare Program
  • Natural Science Foundation of Beijing Municipality
  • Beijing Science and Technology Planning Project
  • Natural Science Foundation of Chongqing
  • Beijing Nova Program
  • Key Project of National Medical Products Administration

Zitieren

APA

Mao, S., Xie, R., Shou, J., Pang, Y., & Sun, W. (2025). Bioprinting of patient-derived heterogeneous renal cell carcinoma organoids for personalized therapy. Biofabrication, 17(4), 045008. https://doi.org/10.1088/1758-5090/adecc5

Vancouver

Mao S, Xie R, Shou J, Pang Y, Sun W. Bioprinting of patient-derived heterogeneous renal cell carcinoma organoids for personalized therapy. Biofabrication. 2025;17(4):045008. doi:10.1088/1758-5090/adecc5

BibTeX
@article{Mao2025,
  author = {Mao, Shuangshuang and Xie, Ruiyang and Shou, Jianzhong and Pang, Yuan and Sun, Wei},
  title = {Bioprinting of patient-derived heterogeneous renal cell carcinoma organoids for personalized therapy},
  journal = {Biofabrication},
  year = {2025},
  volume = {17},
  number = {4},
  pages = {045008},
  doi = {10.1088/1758-5090/adecc5}
}
Kostenlos starten →